ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Dexcom Launches Its First Open Call to Uncover the Next Diabetes Advocates Ahead of World Diabetes Day

  • Now through Sept. 19, people in the U.S. and Canada from 2 years and older living with all types of diabetes and prediabetes can apply for a once-in-a-lifetime opportunity to raise diabetes awareness on a global scale.
  • Selected candidates will be given a global platform to champion the diabetes community while starring in Dexcom’s 2025 World Diabetes Day campaign.

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of its first open call in the U.S. and Canada in search of the next diabetes advocates. Those selected will experience a once-in-a-lifetime opportunity to raise awareness and share their voice on a global scale this World Diabetes Day (Nov. 14) and beyond.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250910746857/en/

Selected candidates will be given a global platform to champion the diabetes community while starring in Dexcom’s 2025 World Diabetes Day campaign.

Selected candidates will be given a global platform to champion the diabetes community while starring in Dexcom’s 2025 World Diabetes Day campaign.

Now through Sept. 19, people from 2 years and older living with all types of diabetes and prediabetes – including Dexcom Warriors* and Stelo ambassadors – can apply at Dexcom.com/WorldDiabetesDay. Those selected will embody strength, advocacy and pride living with diabetes.

“We’ve long believed that real people with diabetes should be the voice of our company, and we’ve fostered that belief through our global Dexcom Warrior and Stelo Ambassador communities,” said Anne Santoro, senior vice president, product marketing at Dexcom. “Now, we’re giving these communities – and anyone living with diabetes who’s passionate about raising awareness – a chance to share their voice on a global stage.”

Those selected will receive an invite to participate in a photoshoot in Los Angeles to have their unique and inspiring story featured in Dexcom’s 2025 World Diabetes Day campaign. They’ll also have ongoing support from Dexcom over the next year to attend events, connect with the diabetes community and continue to advocate for diabetes awareness.

“I never sought to be the face of diabetes advocacy – I just wanted to share my story and hope that it would connect with people,” said Nick Jonas, American multi-platinum recording artist, songwriter, actor and philanthropist. “Over the years, I’ve learned that using our voices to spread messages of support, hope and perseverance can have a major impact on people’s lives, so I’m proud to support this open call and see Dexcom empower people with diabetes to do even more incredible work in their communities.”

To nominate yourself or someone you know, visit Dexcom.com/WorldDiabetesDay. Nominations close Sept. 19 at 12 p.m. PDT.

About Dexcom

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.

*

Dexcom G-Series products are indicated for individuals with T1, T2 or Gestational Diabetes ages 2 years and older

Stelo is cleared by the FDA for adults not on insulin who are 18 or older* in the United States

 

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.22
+21.36 (9.58%)
AAPL  270.37
-1.03 (-0.38%)
AMD  256.12
+1.28 (0.50%)
BAC  53.45
+0.42 (0.79%)
GOOG  281.82
-0.08 (-0.03%)
META  648.35
-18.12 (-2.72%)
MSFT  517.81
-7.95 (-1.51%)
NVDA  202.49
-0.40 (-0.20%)
ORCL  262.61
+5.72 (2.23%)
TSLA  456.56
+16.46 (3.74%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.